Company Overview
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $441.33M (+13.6% YoY); net profit $9.77M.
- Trailing 12 Months Year-on-year growth — revenue +11.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 9.0%, profit CAGR 0.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.97% |
| 1 Year: | 11.30% |
Compounded Profit Growth
| 5 Years: | 0.74% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -46.72% |
| 6 Months: | -38.29% |
| 3 Months: | -10.73% |
| 1 Month: | +1.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)52.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Trading 51.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AORT Artivion, Inc. R2KR3KPHARMA | 23.30 | -332.86 | $1.14B | 0.00% | 3.41% | -0.73% | 8.97% | 0.74% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 45.06M | 47.82M | 44.00M | - | 61.95M | 68.50M | 64.60M | - | 67.50M | 71.14M | 67.88M | - | 66.43M | 53.77M | 65.13M | 71.09M | 76.15M | 72.21M | 77.21M | 80.34M | 76.84M | 83.23M | 89.25M | 87.85M | 97.43M | 98.02M | - | - | 98.98M | 112.97M | 113.39M | 115.99M | 116.34M | 125.76M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 35.40M | 39.86M | 38.99M | 42.85M | 40.89M | - |
| Gross Profit | 22.98M | 26.52M | 27.62M | 30.30M | 29.78M | 31.20M | 29.51M | 32.91M | 29.86M | 36.36M | 39.23M | 45.85M | 42.71M | 45.19M | 44.27M | 46.97M | 45.22M | 46.55M | 44.17M | 35.89M | 43.13M | 47.84M | 50.51M | 47.79M | 50.72M | 52.17M | 48.74M | 53.73M | 58.08M | 56.27M | 62.95M | 63.32M | - | - | 63.58M | 73.11M | 74.39M | 73.14M | 75.45M | 80.52M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 61.43M | 64.73M | 65.36M | 65.96M | 69.66M | - |
| Operating Income | 2.53M | - | 6.65M | 4.59M | 5.48M | - | 2.55M | 4.79M | 829.00K | - | -3.49M | 5.41M | 4.62M | - | 2.21M | 6.50M | 4.70M | - | -1.19M | -1.92M | 3.63M | 1.45M | 1.32M | 14.69M | 1.64M | 4.54M | -4.11M | -3.86M | 7.67M | -1.24M | 25.31M | 6.51M | - | - | 2.15M | 8.38M | 9.04M | 7.18M | 5.79M | -8.36M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.81M | 16.29M | 18.89M | 17.82M | 12.05M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.66M | 7.27M | 6.12M | 5.53M | 5.37M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.29M | 3.48M | 7.06M | 6.54M | 339.00K | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.79M | 2.14M | 554.00K | 4.11M | -1.08M | - |
| Net Income | 2.15M | 2.64M | 2.54M | 2.35M | 2.99M | 2.90M | 2.22M | 3.16M | 1.32M | -3.01M | -3.85M | 226.00K | 1.56M | -776.00K | -297.00K | 2.83M | -134.00K | -681.00K | -6.67M | -3.69M | -2.87M | -3.14M | -2.18M | 10.58M | -3.39M | -4.26M | -13.71M | -13.53M | -3.38M | -9.80M | 7.53M | -2.12M | - | - | -505.00K | 1.34M | 6.50M | 2.43M | 1.42M | -13.51M |
| Diluted EPS | 0.07 | 0.09 | 0.08 | 0.07 | 0.09 | 0.09 | 0.06 | 0.09 | 0.04 | -0.09 | -0.11 | 0.01 | 0.04 | -0.02 | -0.01 | 0.07 | 0.00 | -0.02 | -0.18 | -0.10 | -0.08 | -0.08 | -0.06 | 0.26 | -0.08 | -0.11 | -0.34 | -0.33 | -0.08 | -0.24 | 0.18 | -0.05 | - | - | -0.01 | 0.03 | 0.13 | 0.05 | 0.03 | -0.28 |
| R&D Expense | 2.96M | - | 2.61M | 3.28M | 3.71M | - | 4.09M | 4.73M | 4.28M | - | 5.37M | 5.72M | 5.22M | - | 5.55M | 5.84M | 6.26M | - | 6.36M | 5.52M | 5.75M | 7.75M | 8.36M | 9.97M | 10.13M | 8.65M | 11.80M | 7.22M | 7.42M | 6.42M | 6.95M | 7.50M | 6.61M | - | 6.73M | 7.06M | 8.08M | - | 8.84M | 9.05M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 111.69M | 116.64M | 119.63M | 131.72M | 140.76M | 144.64M | 145.90M | 180.38M | 189.70M | 262.84M | 276.22M | 253.23M | 298.84M | 313.79M | 354.00M | 388.54M | 441.33M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 111.27M | 124.83M | 139.76M | 157.10M |
| Gross Profit | 69.77M | 68.37M | 75.84M | 85.02M | 90.39M | 91.29M | 90.72M | 118.90M | 128.64M | 172.98M | 183.01M | 167.78M | 197.51M | 202.52M | 229.18M | 248.78M | 284.23M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 196.32M | 237.68M | 209.91M | 257.48M |
| Operating Income | 14.50M | 9.87M | 11.64M | 12.61M | 13.82M | 8.84M | 5.35M | 21.82M | 7.97M | 9.31M | 17.04M | 2.44M | 8.12M | 6.20M | -8.51M | 38.87M | 26.75M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.68M | 26.79M | 50.97M | 63.82M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.22M | 25.30M | 34.28M | 26.58M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.98M | -21.59M | -7.51M | 14.78M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.21M | 9.10M | 5.84M | 5.01M |
| Net Income | 8.68M | 3.94M | 7.37M | 7.95M | 16.17M | 7.32M | 4.00M | 10.78M | 3.70M | -2.84M | 1.72M | -16.68M | -14.83M | -19.19M | -30.69M | -13.36M | 9.77M |
| Diluted EPS | 0.30 | 0.14 | 0.26 | 0.28 | 0.57 | 0.25 | 0.14 | 0.32 | 0.11 | -0.08 | 0.05 | -0.44 | -0.38 | -0.48 | -0.75 | -0.32 | 0.21 |
| R&D Expense | 5.25M | 5.92M | 6.90M | 7.26M | 8.45M | 8.70M | 10.44M | 13.45M | 19.46M | 23.10M | 22.96M | 24.21M | 35.55M | 38.88M | 28.71M | 28.45M | 30.99M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 137.44M | 147.86M | 157.16M | 174.68M | 176.16M | 181.18M | 316.14M | 589.69M | 571.09M | 605.65M | 789.40M | - | 762.80M | 792.40M | 789.10M | 884.80M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 247.33M | 280.67M | 290.08M | 358.08M |
| Cash & Equivalents | 17.20M | 30.12M | 35.50M | 21.70M | 13.01M | 37.64M | 33.38M | 37.59M | 56.64M | 39.98M | 41.49M | 33.77M | 61.41M | - | 39.35M | 58.94M | 53.46M | 64.91M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 74.48M | 81.98M | 79.77M | 92.43M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 61.82M | 71.80M | 79.46M | 89.76M |
| Total Liabilities | - | - | 23.50M | 26.33M | 29.04M | 29.94M | 27.47M | 25.93M | 107.16M | 312.63M | 296.02M | 319.96M | 460.69M | - | 478.47M | 510.62M | 512.90M | 436.56M |
| Current Liabilities | - | - | 19.33M | 21.46M | 21.43M | 20.72M | 20.63M | 19.61M | 30.10M | 42.94M | 34.52M | 45.20M | 60.47M | - | 49.67M | 57.86M | 66.82M | 101.56M |
| Long Term Debt | - | - | - | - | - | - | - | - | 67.01M | 218.24M | 215.72M | 214.57M | 290.47M | - | 306.50M | 305.53M | 314.15M | 215.11M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 356.83M | 358.34M | 362.26M | 257.61M |
| Total Equity | 98.37M | 110.45M | 113.94M | 121.54M | 128.11M | 144.75M | 148.69M | 155.25M | 208.98M | 277.06M | 275.07M | 285.70M | 328.71M | - | 284.33M | 281.78M | 276.20M | 448.23M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 41.83M | 42.57M | 43.43M | 49.33M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 16.57M | 20.84M | 16.75M | 18.99M | - | - | 11.44M | 19.72M | 10.80M | 9.88M | 15.83M | 12.37M | - | -5.15M | 18.82M | 22.24M | 39.88M |
| Investing Cash Flow | -4.38M | -10.73M | -27.72M | -22.92M | - | - | -4.49M | -78.91M | -171.05M | -6.71M | -23.94M | -73.13M | - | -10.71M | -502.00K | -28.19M | -42.04M |
| Financing Cash Flow | 707.00K | -4.72M | -2.85M | -4.71M | - | - | -2.81M | 73.43M | 143.25M | -2.56M | -1.49M | 93.61M | - | -1.64M | 865.00K | 2.20M | 11.28M |
| Capital Expenditure | -1.69M | -2.12M | -2.54M | -3.07M | -4.34M | -4.31M | -3.49M | -6.20M | -6.63M | -5.79M | -8.07M | -7.33M | - | -10.71M | -9.75M | -11.19M | -39.04M |
| Free Cash Flow | 14.88M | 18.72M | 14.21M | 15.92M | - | - | 7.95M | 13.52M | 4.17M | 4.09M | 7.75M | 5.04M | - | -15.87M | 9.07M | 11.05M | 839.00K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.51M | 19.19M | -3.75M | 9.12M |
| Share Buybacks | 330.00K | 5.88M | 3.06M | 3.31M | 1.52M | 5.59M | - | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | - | - | - | 1.37M | 2.97M | 3.29M | 3.41M | - | - | - | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 62.5% | 58.6% | 63.4% | 64.5% | 64.2% | 63.1% | 62.2% | 65.9% | 67.8% | 65.8% | 66.3% | 66.3% | 66.1% | 64.5% | 64.7% | 64.0% | 64.4% |
| Operating Margin % | 13.0% | 8.5% | 9.7% | 9.6% | 9.8% | 6.1% | 3.7% | 12.1% | 4.2% | 3.5% | 6.2% | 1.0% | 2.7% | 2.0% | -2.4% | 10.0% | 6.1% |
| Net Margin % | 7.8% | 3.4% | 6.2% | 6.0% | 11.5% | 5.1% | 2.7% | 6.0% | 2.0% | -1.1% | 0.6% | -6.6% | -5.0% | -6.1% | -8.7% | -3.4% | 2.2% |
| ROE % | 7.9% | 3.5% | 6.1% | 6.2% | 11.2% | 4.9% | 2.6% | 5.2% | 1.3% | -1.0% | 0.6% | -5.1% | - | -6.7% | -10.9% | -4.8% | 2.2% |
| ROCE % | - | 8.4% | 9.2% | 9.3% | 9.0% | 5.7% | 3.3% | 7.6% | 1.5% | 1.7% | 3.0% | 0.3% | - | 0.9% | -1.2% | 5.4% | 3.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 13.69% | 6.67M | $141.89M |
| 2 | Nomura Asset Management International Inc | 6.53% | 3.18M | $67.71M |
| 3 | Morgan Stanley | 5.25% | 2.56M | $54.38M |
| 4 | Juniper Investment Company, LLC | 4.14% | 2.02M | $42.94M |
| 5 | Vanguard Capital Management LLC | 4.11% | 2.00M | $42.62M |
| 6 | FMR, LLC | 4.03% | 1.96M | $41.74M |
| 7 | State Street Corporation | 3.81% | 1.86M | $39.50M |
| 8 | Ophir Asset Management Pty Ltd | 3.69% | 1.80M | $38.27M |
| 9 | Perceptive Advisors Llc | 3.56% | 1.74M | $36.93M |
| 10 | Conestoga Capital Advisors, LLC | 3.33% | 1.62M | $34.52M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AORT
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2026 financial results will be released on Thursday, November 5, 2026, after the market closes. On tha…
Medical devices & supplies - cardiology, neurology, vascular stocks Q2 teardown: Artivion (NYSE:AORT) vs the rest
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Artivion (NYSE:AORT) and its peers.
Artivion rises as Jefferies initiates at buy, sees ’attractive entry point’
Investing.com -- Artivion Inc (NYSE:AORT) shares gained 4.2% Tuesday after Jefferies initiated coverage on the cardiovascular medical device maker with a Buy rating and a $31 price target, framing the company as a compelling play on aortic …
Artivion (AORT) Stock May Be 13% Undervalued On Cash Flow
Artivion has gone through a sharp reset in market expectations, with the share price down heavily over the past year yet still well ahead of where it was three years ago. That mix of long term gains and recent weakness puts the focus square…
1 Small-Cap Stock with Exciting Potential and 2 We Turn Down
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and stayi…
2 Growth Stocks with All-Star Potential and 1 We Find Risky
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.…
AORT — Frequently Asked Questions
What is the current share price of Artivion, Inc. (AORT)?
As of 2026-10-23 16:27 PDT, Artivion, Inc. (AORT) trades at $23.30 on NYSE. Its 52-week range is $20.10 to $47.63.
What is the market capitalisation of AORT?
Artivion, Inc. (AORT) has a market capitalisation of $1.14B on NYSE.
What is the P/E ratio of AORT?
AORT trades at a trailing price-to-earnings (P/E) ratio of -332.86. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.32.
What is the return on equity (ROE) of AORT?
AORT has a return on equity (ROE) of -0.73%. Its return on capital employed (ROCE) is 3.41%.
Is AORT a good stock to buy?
This page provides a data-driven analysis of Artivion, Inc. (AORT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.